当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Sellouti M*, Ayad A, Abilkassem R and Agadr A
Thousands of cases of multisystem inflammatory syndrome in children (MIS-C) have already been reported in children; however, it’s rarely reported in new-borns. MIS-C is a post-infectious immune-mediated condition that typically occurs 3–5 weeks after COVID-19 infection. It usually presents with fever and multi-organ involvement, and blood investigations often show increased inflammatory markers weeks several weeks after exposure to SARS-CoV-2. A 25-day-old male neonate was admitted to the neonatal intensive care unit with symptoms of multi-organ dysfunction
affecting the cardiovascular, respiratory, and haematological systems. The patient exhibited positive inflammatory markers, high levels of ferritin and D-dimer, and elevated cardiac enzymes. Blood cultures were negative for any infection. PCR of nasopharyngeal swab material was positive for respiratory pathogens. Serological tests conducted on both the mother and the patient showed negative results for anti-spike SARS-CoV-2 IgM and anti-nucleocapsid SARSCoV-2 IgG. The patient was diagnosed with neonatal multisystem inflammatory syndrome (MIS-N) and successfully
treated with two doses of intravenous immunoglobulin (1 g/kg/dose) and methylprednisolone (2 mg/kg/day for 5 days). MIS-N related to SARS-CoV-2 can present with cardiorespiratory compromise and carry a higher risk of adverse outcomes in neonates.